Suppr超能文献

局部回归与调强放疗治疗 T1-2 期鼻咽癌的对照研究。

Local regression and control of T1-2 nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.

机构信息

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Department of Oncology, Shanghai Medical College, Shanghai, China.

出版信息

Cancer Med. 2018 Dec;7(12):6010-6019. doi: 10.1002/cam4.1866. Epub 2018 Nov 8.

Abstract

OBJECTIVE

To observe the local regression and control in T1-2 nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiotherapy (IMRT) and to analyze the related influencing factors.

METHODS

Between January 2006 and June 2014, 247 consecutive T1-2 NPC patients treated with IMRT were retrospectively analyzed, with 126 (51.0%) N0-1 disease and 121 (49.0%) N2-3 disease. Among them, 72.9% received platinum-based chemotherapy. The prescribed dose to gross tumor volume was 66 Gy/30 fractions.

RESULTS

By the end of IMRT, the chemoradiotherapy (CRT) group had higher local complete response (CR) rate compared with IMRT alone group (92.2% vs 74.6%, P < 0.001), but no significant difference was discovered in 5-year local control (LC) rate (95.1% vs 94.9%, P = 0.968). Of the rest 31 patients with residual nasopharyngeal lesions after IMRT, those received boost irradiation (67.7%) also showed no improvement in 5-year LC rate compared with the observational group (95.0% vs 100.0%, P = 0.307). With a median follow-up of 63 months, the estimated 5-year LC rate for the whole group was 95.1% (T1 vs T2: 95.9% vs 94.7%, P = 0.186). Prognostic factors for LC were found neither in univariate nor in multivariate analysis. Advanced N stage was found to be the only adverse prognostic factor for all the other survivals.

CONCLUSIONS

Excellent LC could be achieved in T1-2 NPC treated with IMRT. The addition of chemotherapy may offer short-term response benefit, but no significant LC benefit, so did boost irradiation. Attention should be attached to advanced N stage, the exploration of the recurrence-related factors, and the necessities of the additional treatment.

摘要

目的

观察调强放疗(IMRT)治疗 T1-2 期鼻咽癌(NPC)患者的局部回归和控制情况,并分析相关影响因素。

方法

回顾性分析 2006 年 1 月至 2014 年 6 月期间 247 例接受 IMRT 治疗的 T1-2 NPC 患者,其中 N0-1 期疾病 126 例(51.0%),N2-3 期疾病 121 例(49.0%)。其中 72.9%的患者接受了铂类为基础的化疗。大体肿瘤体积的规定剂量为 66Gy/30 次。

结果

在 IMRT 结束时,放化疗组的完全缓解(CR)率高于单纯 IMRT 组(92.2% vs 74.6%,P<0.001),但 5 年局部控制率(LC)无显著差异(95.1% vs 94.9%,P=0.968)。在 IMRT 后仍有残留鼻咽病变的 31 例患者中,接受推量照射的患者(67.7%)5 年 LC 率也无改善(观察组为 95.0%,对照组为 100.0%,P=0.307)。中位随访 63 个月时,全组 5 年 LC 率为 95.1%(T1 期 vs T2 期:95.9% vs 94.7%,P=0.186)。单因素和多因素分析均未发现 LC 的预后因素。晚期 N 期是所有其他生存结果的唯一不良预后因素。

结论

IMRT 治疗 T1-2 NPC 可获得良好的 LC。化疗的加入可能会带来短期的反应获益,但对 LC 没有显著获益,推量照射也是如此。应注意晚期 N 期,探索与复发相关的因素,以及是否需要额外的治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd53/6308044/a3831cb7dc2e/CAM4-7-6010-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验